A carregar...
ASCO 2016: highlights in breast cancer
At the 2016 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented. MA17.R was the first randomized phase III trial to evaluate the prolongation of adjuvant aromatase-inhibitor (AI) therapy from 5 to 10 years; while a significant reduction of disease-free surviva...
Na minha lista:
| Publicado no: | Memo |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Vienna
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5165027/ https://ncbi.nlm.nih.gov/pubmed/28058064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-016-0300-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|